Crinetics Pharmaceuticals Receives EU Approval for PALSONIFY (Paltusotine), First Oral Daily Acromegaly Treatment

Key Takeaways

• PALSONIFY becomes the first once-daily oral therapy approved for acromegaly treatment in the European Union
• Approval covers both treatment-naïve and previously treated adult patients based on two pivotal Phase 3 studies
• Crinetics plans initial launch in Germany and Austria, marking the company’s first regulatory approval outside the United States

---

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced on April 27, 2026, that the European Commission has approved PALSONIFY® (paltusotine) for treating acromegaly in adults, representing a breakthrough as the first once-daily oral therapy for this rare endocrine disorder in the European Union.

Regulatory Milestone Based on Strong Clinical Evidence

The approval stems from robust data generated in two pivotal Phase 3 clinical studies that evaluated PALSONIFY’s efficacy and safety in both medical treatment-naïve patients and those previously treated for acromegaly. This comprehensive clinical program demonstrates the therapy’s potential across the full spectrum of acromegaly patients.

Acromegaly, a rare hormonal disorder caused by excess growth hormone production, typically affects 3-4 people per million annually. Current treatment options primarily consist of injectable somatostatin analogs and growth hormone receptor antagonists, making PALSONIFY’s oral formulation a significant advancement in patient convenience and quality of life.

IntelligenceRegulatory Impact▾

EMA and MHRA are the agencies to watch. Regulatory relevance reads medium for endocrinology - acromegaly, with PALSONIFY and Paltusotine most exposed to upcoming decisions. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Market Impact and Launch Strategy

This European Commission approval marks Crinetics’ first regulatory success outside the United States, establishing the company’s international presence in the rare disease pharmaceutical market. The company has announced plans to initiate commercial launch in Germany and Austria first, likely targeting these markets due to their robust healthcare infrastructure and established rare disease treatment protocols.

The oral administration route represents a competitive advantage over existing injectable therapies, potentially improving patient adherence and treatment satisfaction. Healthcare providers have long sought more convenient treatment options for acromegaly patients, who typically require lifelong management.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Implications for Crinetics and the Acromegaly Market

PALSONIFY’s approval validates Crinetics’ drug development platform and positions the company to capture market share in the European acromegaly treatment landscape. While the patient population remains relatively small, rare disease therapies often command premium pricing due to their specialized nature and limited competition.

The success in Europe may also strengthen Crinetics’ position for potential regulatory submissions in other markets, including a possible U.S. FDA filing. The company’s ability to demonstrate efficacy across different patient populations—both treatment-naïve and experienced—broadens the potential commercial opportunity.

IntelligenceMarket Signals▾

Commercial pull is medium and investment relevance low. Expect implications for endocrinology - acromegaly pricing, access, and launch sequencing.

Looking Forward

The approval represents more than just a new treatment option; it signifies a shift toward more patient-friendly acromegaly management. As Crinetics prepares for commercial launch, the company will need to navigate European reimbursement processes and establish relationships with endocrinologists and specialized treatment centers.

For the broader pharmaceutical industry, PALSONIFY’s approval demonstrates the continued innovation potential in rare disease therapeutics, where patient convenience and quality of life improvements can drive significant clinical and commercial value.

---

Frequently Asked Questions

What makes PALSONIFY different from existing acromegaly treatments?

PALSONIFY is the first once-daily oral therapy for acromegaly approved in the EU, offering significant convenience advantages over current injectable treatments like somatostatin analogs, potentially improving patient adherence and quality of life.

When will PALSONIFY be available to European patients?

Crinetics plans to launch PALSONIFY first in Germany and Austria following the European Commission approval. Specific availability dates will depend on country-specific regulatory processes and reimbursement negotiations.

Which patients can receive PALSONIFY treatment?

The approval covers adults with acromegaly, including both treatment-naïve patients and those previously treated with other therapies, based on data from two pivotal Phase 3 studies demonstrating efficacy across these patient populations.

IntelligenceStrategic Takeaways▾

PALSONIFY becomes the first once-daily oral therapy approved for acromegaly treatment in the European Union Approval covers both treatment-naïve and previously treated adult patients based on two pivotal Phase 3 studies Crinetics plans initial launch in Germany and Austria, marking the company’s first regulatory approval outside the United States

Related profiles

• PALSONIFY
• paltusotine

Related coverage

• EMA's CHMP Recommends Oral Wegovy Approval, Expanding Obesity Treatment Options in Europe
• CinnaGen's Zandoriah Achieves EU Approval for Osteoporosis Treatment
• Quoin Pharmaceuticals Aims for First Peeling Skin Syndrome Trial with FDA IND Submission